Success Metrics

Clinical Success Rate
95.2%

Based on 40 completed trials

Completion Rate
95%(40/42)
Active Trials
0(0%)
Results Posted
48%(19 trials)
Terminated
2(5%)

Phase Distribution

Ph phase_1
8
19%
Ph phase_3
18
42%
Ph phase_2
1
2%
Ph phase_4
14
33%

Phase Distribution

8

Early Stage

1

Mid Stage

32

Late Stage

Phase Distribution41 total trials
Phase 1Safety & dosage
8(19.5%)
Phase 2Efficacy & side effects
1(2.4%)
Phase 3Large-scale testing
18(43.9%)
Phase 4Post-market surveillance
14(34.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.2%

40 of 42 finished

Non-Completion Rate

4.8%

2 ended early

Currently Active

0

trials recruiting

Total Trials

43

all time

Status Distribution
Completed(40)
Terminated(2)
Other(1)

Detailed Status

Completed40
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
43
Active
0
Success Rate
95.2%
Most Advanced
Phase 4

Trials by Phase

Phase 18 (19.5%)
Phase 21 (2.4%)
Phase 318 (43.9%)
Phase 414 (34.1%)

Trials by Status

terminated25%
completed4093%
unknown12%

Recent Activity

Clinical Trials (43)

Showing 20 of 43 trialsScroll for more
NCT00460512Phase 3

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

Completed
NCT00549562Phase 3

Study of Paliperidone ER in Adolescents and Young Adults With Autism

Completed
NCT00488319Phase 3

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Completed
NCT01050478Phase 4

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Completed
NCT02433717Phase 4

A Pharmacokinetic Study of Paliperidone ER

Unknown
NCT01157585Phase 4

Efficacy and Safety of Paliperidone ER in First Episode Psychosis

Completed
NCT00490971Phase 3

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Completed
NCT00309699Phase 3

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

Completed
NCT00524043Phase 4

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

Completed
NCT00535132Phase 4

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Completed
NCT00412373Phase 3

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Completed
NCT00645099Phase 3

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Completed
NCT01662648Phase 3

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Completed
NCT00697658

INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

Completed
NCT00518323Phase 3

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Completed
NCT02075528Phase 4

Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER

Completed
NCT00934635Phase 4

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Terminated
NCT00757705Phase 4

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Completed
NCT01577186Phase 4

Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)

Completed
NCT01577160Phase 4

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
43